Abstract. A series of variously substituted furochromenes, hemiacetals 2, acetals 3, and rearranged compounds 4, were synthesized from variously substituted 4-hydroxycoumarins and evaluated in several in vitro assays, inhibition of mast cell degranulation induced by the activation of Fcε receptor type I or calcium ionophore and leukotriene B 4 (LTB 4 ) inhibition. The most active derivatives, 3p and 4p (8-iso-propyl substitution in coumarin ring) and 3r (5-methyl-8-chloro substitution), showed significant inhibition of mast cell degranulation (Fctriggered) and LTB 4 , and exhibited significant local anti-inflammatory activity in PMA induced ear edema in CD1 mice, with potency equal (compounds 3p and 4p) or better (compound 3r) in comparison with zileuton, a reference drug used. It might be a promising direction for developing novel drugs as potential agents for the treatment of allergies and other inflammatory diseases.(doi: 10.5562/cca2240)
INTRODUCTION
Coumarins represent an important class of oxygenated heterocycles. Since many of them, both naturally occurring and synthetic, possess diverse array of biological activities, they are also of potential pharmaceutical interest. In nature they act as plant growth regulation factors, UV-filters and protectors from sun radiation, or as insecticides, antivirals or antibacterial agents. 1 4-Hydroxycoumarin was determined as a building unit of natural product dicoumarol, isolated from spoiled sweet clover and identified as a causative agent of haemorrhagic cattle deaths. 2 The intensive investigations of many natural and synthetic coumarins resulted in discovery of warfarin and other 3-alkyl-4-hydroxycoumarins as potent, clinically used anticoagulants, [3] [4] [5] [6] [7] [8] mainly used in postsurgical prevention of wound induced thrombus formation. Intensive investigation on the molecular level of action of these compounds showed that they prevent reduction of vitamin K epoxide to active vitamin K thus inhibiting the biosynthesis of protrombin and other clothing factors. 9 Coumarins belonging to different chemical classes have been studied. 10 There are evidences of the antiretroviral activity of coumarin derivatives and their ability to inhibit HIV integrase.
11-14 Some 3-aryl and 3-heteroaryl derivatives are inhibitors of macrophage migration inhibitory factor (MIF), 15 while natural coumarin product cnidicin 16 ( Figure 1 ), isolated from the root extract of Angelica koreana (Umbelliferae), is an active component responsible for the inhibitory effect on the degranulation process of cultured mast cells. Cnidicin demonstrated a significant inhibition upon the release of -hexosaminidase from the cultured RBL-2H3 cells in a dose dependent manner and the IC50 value was calculated as 25 ± 2.1 M, which is comparable to that of azelastine (26 ± 3.2 M) an anti-allergic drug known to inhibit the degranulation of mast cells.
This result implied an anti-allergic action of cnidicin in vitro.
Another coumarin compound, selinidin ( Figure  1 ), 17 isolated from the extract of A. keiskei is an antiallergic compound in screening employing rat basophilic leukemia RBL-2H3 cells. Selinidin had an inhibitory effect on degranulation of RBL-2H3 cells upon engagement of Fcε receptor type I with IgE and antigen. Furthermore, it was shown that selinidin modulates Fcε receptor type I mediated signaling although it does not prevent IgE-Fcε receptor type I binding and cell surface Fcε receptor type I expression. These results suggest that selinidin suppresses IgE-mediated mast cell activation by inhibiting signal transduction pathways through Fcε receptor type I.
Also, it was documented that some synthetic aryl substituted 3-tetrazolylcoumarins, 18 ,19 and 3-nitro-4-hydroxycoumarins 20, 21 inhibit degranulation of mast cells thus preventing release of chemical mediators such as cysteinyl leukotrienes C 4 , D 4 and E 4 (originally described as slow-reacting substances of anaphylaxis, SRS-A) and histamine. In addition, a broad array of other therapeutic applications of natural and synthetic coumarins has been reported in the literature, especially concerning their anti-inflammatory / antioxidant properties, [22] [23] [24] [25] their application as neuroprotecting agents, 26 as well as in pharmacotherapy of breast cancer. 27 Furocoumarins are a class of natural and synthetic compounds used as photoreactive, antiviral, antiinflammatory agents as well as kinase inhibitors. 28 Furo [4,3-c] coumarins are generally prepared by condensation of aryl substituted 4-hydroxycoumarins as dinucleophiles and vicinal dielectrophiles. 26, 29 In a quest for new anti-inflammatory / antiallergic therapeutics we screened our compound collection in mast cell degranulation assays and leukotriene B 4 assay. Here, we wish to present the synthesis of several so far unreported classes of coumarin compounds, variously substituted furochromenes 2-4, as well as to report the results on evaluation of their biological activity.
Anti-inflammatory activity of prepared compounds was examined on the basis of in vitro tests, inhibition of mast cell (RBL-2H3 cell line of rat basophilic leukaemia) degranulation induced by the activation of Fcε receptor type I. There is significant evidence that mast cells, basophils, and their released mediators are primary effectors of allergic inflammation. Mast cells may contribute to the pathophysiology of a wide variety of diseases including asthma, cardiomyopathy, schleroderma, arthritis, and fibrotic lung disorders. It is believed that many of the deleterious effects that mast cells mediate are due to a variety of proinflammatory molecules exocytosed with exposure to antigen and the subsequent crosslinking of cell-surface-bound immunoglobulin E (IgE), including histamine, serotonin, and the proteases tryptase, chymase, and carboxypeptidase. Furthermore, mast cell activation results in the release and increased production of cytokines including interleukins 4-6, tumor necrosis factor-alpha, prostaglandin D 2 , and leukotrienes A 4 and C 4 . Clearly, modulation of mast cell activation and degranulation could significantly affect a number of disease states.
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The inhibition of degranulation may prevent the symptoms and arrest the inflammation progress, which has been proven by the clinical use of degranulation inhibitors (sodium chromoglycate, nedochromyl sodium and ketotifen). Cysteinyl leukotriene antagonists have also proven efficacy in asthma therapy. 31 Therapeutically, the 5-lipoxygenase inhibitor, zileuton, is as effective as cysteinyl leukotriene antagonists, and its therapeutic effects are indistinguishable from those of the cysteinyl leukotriene antagonists. Number of LTB 4 antagonists were reported as well. 32 Discovery of new generation of compounds which would inhibit mast cell degranulation as well as prevent synthesis of leukotrienes potentially provides a therapeutic approach for treatment of allergies and other inflammatory diseases.
Anti-inflammatory potential of selected compounds was also evaluated in the in vivo antiinflammatory model of phorbol 12-myristate 13-acetate (PMA) induced ear oedema in CD1 mice. Mouse ear inflammation induced by different irritants, including PMA provides a range of skin inflammation models suitable for the evaluation of both topical and systemic anti-inflammatory agents.
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EXPERIMENTAL SECTION
General methods
Starting 4-hydroxycoumarins 1a, d, f-h and l were commercially available. All other 4-hydroxycoumarins 1b-c, e, i-k, m-r were synthesised according to protocols described in literature 34 and references cit- 
Synthesis
General synthetic methodology for Furochromenes 2-4
General methodology to prepare hemiacetals 2. Appropriate 4-hydroxycoumarin 1 (1 mmol) was mixed with a 40 % aqueous solution of glyoxal (2.5 mmol). Acetonitrile (5-10 ml) was added thereto and the reaction mixture was refluxed for 2-6 hours. After cooling the product was filtered and washed with acetonitrile, affording hydroxy furochromen derivatives 2a-p as pure compounds.
General methodology to prepare acetals 3. Into a solution of appropriate 4-hydroxycoumarin 1 (1 mmol) in MeOH (5 ml) was added aqueous dimethoxyacetaldehyde (60 % solution, 8 mmol). Reaction mixture was stirred at reflux temperature for 5 hours. After cooling to room temperature, product was collected by filtration and washed with MeOH, affording 3a-r as pure compounds.
General methodology to prepare rearranged compounds 4. Appropriate metoxy furochromen derivative 3 (0.3 mmol) was suspended in acetic acid (5 ml). The reaction mixture was refluxed for 1-24 hours, whereat the starting material was dissolved, and then a precipitate was formed. After cooling to the room temperature the product was collected by filtration and washed with acetic acid and diethyl ether, affording furochromen derivatives 4 as pure compounds.
Synthetic procedure for enol ether 5. To a suspension of 2a (0.412 mmol) in Me 2 CO (10 ml) powdered anhydrous K 2 CO 3 (2.89 mmol) was added, followed by Me 2 SO 4 (2.12 mmol). Reaction mixture was heated to reflux and vigorously stirred for 24 hours, cooled to room temperature, followed by filtration. The filtrate was evaporated to dryness and the residue then triturated with ice-cold water for 10 minutes, filtered off and recrystallized from MeOH (140 mg / 25 ml) to obtain product 5.
Synthetic procedure for acetylation of compound 3a. A suspension of 3a (1.05 mmol) in Ac 2 O (12 ml) was stirred at reflux for 1 h. After cooling to room temperature, resulting precipitate was collected by filtration, washed with CH 3 CN to afford product 6, which was further recrystallized from Ac 2 O. [3,2c] 
2-hydroxy-3-(4-hydroxy-2-oxo-2H-chromene-3-yl)-2,3-dihydro-4H-furo
3-(4-hydroxy-2-oxo-2H-benzo[g]chromene-3-yl)-2-methoxy-2,3-dihydro-4H-benzo[g]furo[3,2-c]chromene-4-one (3a
2-(4-hydroxy-2-oxo-2H-chromene-3-yl)-4H-furo[3,2-c]chromene-4-one (4a
1,1-bis(4-methoxy-2-oxo-2H-chromen-3-yl)-2-methoxyethene (5)
.
3-(4-acetoxy-2-oxo-2H-chromen-3-yl)-2,3-dihydro-2-methoxy-4H-furo[3,2-c]chromen-4-one (6
X-Ray Crystallography
Crystal structures of compounds 5 and 6 were determined by the single crystal X-ray diffraction method. Data were collected at 100 K with a Kappa-CCD Nonoius diffractometer using graphite monochromated CuK radiation. Data reduction was carried out using DENZO and SCALEPACK 35 software. The details of crystal data collection and refinement parameters for compounds 5 and 6 are listed in Table 1 . Further details on crystal structure investigation are available free of charge on application to CCDC, 12 Union Road, Cambridge CB2 IEZ, UK, www.ccdc.ac.uk/conts/retrieving.html or deposit@ccdc.cam.ac.uk under following deposition numbers; CCDC 941948 for compound 5 and CCDC 941949 for compound 6.
The structure was solved by direct methods implement in SHELXS97 36 and refined by a full-matrix leastsquares method based on F 2 using SHELXL97. 35 Hydrogen atoms were positioned geometrically at calculated positions and allowed to ride on their parent atoms.
Computational Studies
Geometry optimization of examined compounds was performed using the density functional theory (DFT) at B3LYP 37,38 level with 6-31G(d,p) basis set. Zero-point vibration energy (ZPVE) correction with scaling factor -induced degranulation by means of a calcium ionophore, the solution A23187 (Calbiochem) in a final concentration of 250 ng ml −1 , were added to the wells. In the case of the negative control wells, pure DMEM medium was added. The cells were incubated for one hour at 37 °C, 5 % CO 2 , and 90 % relative humidity. Each dilution as well as the positive and the negative controls were performed in triplicate.
The supernatant (50 μl) was transferred in duplicate to a 96-well plate. Thereto 100 μl of 50 mM sodium citrate buffer with 1 mg ml -1 para-nitrophenyl-N-acetyl-β-D-glucosaminide (Calbiochem) were added and it was incubated for 1 hour at 37 °C. The reaction was stopped with 100 μl of a saturated sodium carbonate solution. The absorbance was measured at 405 nm. The percentage of inhibition was expressed by the formula: % inhibition = (1-(OD 405 sample -OD 405 negative control) / (OD 405 positive control -OD 405 negative control)) × 100.
Ketotifen, used as a standard, significantly inhibits degranulation in concentrations from 200-50 M.
Leukotriene B 4 (LTB 4 ) Inhibition Assay
Compounds were assayed for their ability to inhibit the production of leukotriene B 4 in A23187 stimulated RBL-2H3 cells. RBL-2H3 cell line (ATCC 2256) is grown in DMEM medium (Invitrogen) supplemented with 10 % FBS (Invitrogen) in the atmosphere of 5 % CO 2 , 90 % humidity, 37 °C. Cells are trypsinazed, washed with fresh DMEM medium and adjusted to 1 × 10 5 cells / ml. 500 l / well of cell suspension is transferred into 24 well plate (Falcon) and grown overnight in culturing condition described herein. 10 mM solutions of tested compounds are prepared in DMSO (Sigma), and dissolved in working concentrations in DMEM medium without phenol red (Invitrogen). Dilutions of tested compounds are placed on cells, whereas for positive and negative controls only DMEM medium without phenol red are used and left in culturing conditions for 30 minutes. A23187 (Sigma) was added into all wells except negative controls in the final concentration of 250 nM and left for 45 minutes in culturing conditions. 10 l of cellular supernatant was used to determine leukotriene B 4 levels using ELISA (R&D systems). Total concentrations of LTB 4 are calculated in samples and total inhibition was calculated using the formula:
% inhibition = (1 -LTB 4 sample concentration / LTB 4 positive control concentration) × 100.
Phorbol 12-myristate 13-acetate (PMA) Induced Ear Oedema in CD1 Mice
Male CD1 mice (Iffa Credo, France) weighing ≈ 35-40 g were randomly grouped (n = 8 in vehicle treated test group, dexamethasone treated control group as well as in groups treated with compounds to be assayed). Test compounds, dexamethasone as well as vehicle (Transphase Delivery System, containing benzyl alcohol 10 %, acetone 40 % and isopropanol 50 %) (all from Kemika, Croatia), were administered topically to the internal surface of the left ear thirty minutes prior to administration of phorbol 12-myristate 13-acetate (PMA) (Alexis biochemicals, USA). Test compounds were administered at a single dose of 250 or 100 g / 15 µl / ear and dexamethasone at a single dose of 50 g / 15 µl / ear. Thirty minutes later, 0.01 % PMA solution in acetone was applied topically to the same area of each animal in a volume of 12 µl / ear. During the treatment and challenge, animals were anaesthetized by using inhalation anaesthesia. Six hours after the challenge, animals were euthanized by asphyxiation in 100 % CO 2 atmosphere. For assessing the auricular oedema, 8 mm discs were cut out of left and right auricular pinna and weighed. The degree of oedema was calculated by subtracting the weight of 8 mm disc of the untreated ear from that of the treated contralateral ear.
The compound at appropriate dose is considered active if the supression of ear oedema in compound treated group is statistically significantly different in comparison to positive control group, as calculated by the non-parametric ANOVA statistical method (statistical analysis was done using the program GraphPad 
RESULTS AND DISCUSSION
Chemistry
The compounds under study were prepared by condensation reaction of variously substituted hydroxycoumarins with glyoxal or dimethoxyacetaldehyde as dielectrophiles via tandem Knöevenagel / Michael addition reaction, followed by annulation and dihydrofuran ring formation (Scheme 1). When reaction was performed in nonnucleophilic solvent, such as acetonitrile, hemiacetals 2 were isolated as final products while acetals 3 were isolated after condensation in alcoholic solvent, e.g. methanol (as exemplified in this paper) or ethanol (not shown). Treatment of either 2 or 3 with dehydrating agents such as acetic acid or trifluoroacetic acid (TFA) resulted in the formation of new class of 2-substituted furo [3,2-c] Keto-enol tautomerism is the most common structural isomerism in 4-hydroxycoumarins. Due to dynamic equilibrium tautomers are rapidly interconvertible from one isomeric form to another and tautomer determination is quite challenging. 43 Other structural isomers are possible as well. In our studies we noticed that in compounds 2 ring-chain tautomerism 44 also exists (Scheme 2). Which of the isomeric form prevails in the mixture, cyclic (hemiacetal) or open chain (aldehyde), depends on the nature and number of the aromatic substituents, whether the compound is in a free acid form or as a salt. Type of the salt, type of the solvent in which the compound is dissolved, as well as the pH value of the solution also have an effect on the tautomer ratio.
For the purpose of structure elucidation NMR spectra of investigated compounds were run in DMSOd 6 . The cyclic form (i.e. 2a-A) prevails in such solutions with anomeric proton (H-2) at ppm 6.2 and H-3 at 4.8. Existence of open chain form was confirmed by standard methylation reaction with dimethyl sulphate in the presence of potassium carbonate. Enol ether 5 was isolated as the only reaction product (Scheme 2). The molecular and crystal structures of 5 were determined by single-crystal X-ray diffraction ( Figure 2 , Table 1 ).
Both series of compounds 2 and 3 contain two stereocenters and therefore 4 possible stereoisomers could be expected. However, the pair of enantiomers with trans-configuration around C2-C3 bond in 3 is calculated to be more favorable (Figure 3) , which was determined experimentally as well.
Acetylation of 3a afforded compound 6 (Scheme 3), whose molecular and crystal structures ( Figure 4) were determined by single-crystal X-ray diffraction (Table 1) and product was shown to be a racemic mixture with trans configuration around C2-C3 bond, suggesting (trans)-diastereoselectivity in the formation of acetal 3a. 
Pharmacology
The synthesized compounds were evaluated for their anti-inflammatory activity in the in vitro RBL-2H3 rat mast cells degranulation which was Fcreceptor or Ca 2+ -triggered, and by inhibition of leukotriene B 4 (LTB 4 )at inhibitor concentration of 10 M. 45 For most of them Fc receptor triggered degranulation were repeated with inhibitor concentration of 30 M indicating dose-response behavior of analyzed compounds. Results are summarized in Tables 2-4. Compounds that significantly inhibited (i.e. 50 % or higher) degranulation of mast cells or LTB 4 are considered to be fully "active" and to possess anti-inflammatory activity.
The central role of the mast cell in the initiation of allergic responses makes it an ideal target for antiallergic drug therapy. Mast cells are the primary initiating cells of immediate hypersensitivity reactions so their degranualtion is indicated as invoked in immediate or delayed type hypersensitivity reaction, allergy, anaphylaxis, inflammation, asthma and urticaria. 46 Immunological activation of mast cells results not only in degranulation but also in the liberation of arachidonic acid from phospholipids in the cell membrane. Their further metabolism may proceed along either of two independent pathways, the cyclooxygenase pathway toward prostaglandins and the lypoxygenase pathway which has the capacity to generate a wide variety of leukotriene products. Leukotrienes are important mediators in host defense mechanisms and in inflammatory disease states due, for example, to their effects on cell migration, muscle contraction, vascular permeability, and the release of lysozomal enzymes. 47 It was observed that majority of studied compounds inhibit mast cells degranulation triggered by Fc receptorand only few of them inhibit degranulation triggered by Ca 2+ . Significant inhibition of mast cell degranulation induced by the activation of Fcε receptor type I showed certain derivatives with alkyl and halogen substituents as well as combinations of those substituents, whereas unsubstituted compounds and those with hydroxy and methoxy substituents gave the poorest inhibitions. Further, hemiacetals 2 proved to be the most active ones, regarding the in vitro activity, but during evaluation were proven to be chemically unstable and because of that were not fully investigated. 48 Acetals 3 and rearranged compounds 4 are equally potent inhibitors of mast cell (RBL-2H3) degranulation (Fctriggered).
The most potent inhibitors of Fctriggered mast cell degranulation bear liphophilic substituent at R 4 position. The potency of derivatives at R 4 follows the tendency of 2-4p (isopropyl) > 2-4n (ethyl). Methyl at R 4 is well tolerated in combination with additional methyl group at R 1 position as in 2-4i. Introduction of lipophilic substituent at R 3 position, like chlorine in 2-4e and methyl in 2g and 4g has positive effect on Fctriggered inhibition of mast cell degranulation, especially in combination with additional substitution with methyl at R 1 as in compounds 2-4j. However, R 1 / R 3 combination in 2-4j was somewhat less potent than R 1 / R 4 in 2-4i. Finally, R 2 position tolerates only lipophilic substituents, and the inhibitory potency of derivatives followed the tendency of 2-4o (isopropyl) > 2-4d (chlorine) > 2-4m (ethyl). Less lipophilic or polar groups like methyl (2-4f), hydroxy (2-4b), methoxy (2- 4c), were not tolerated and led to almost complete loss of activity. Introduction of additional methyl group at R 3 position increase activity, and generally it was determined that disubstituted R 2 / R 3 (2-4h and 2-4l) derivatives were more potent that monosubstituted R 2 analogues (2-4f and 2-4d, respectively). On the other hand, influence of substitutions on LTB 4 inhibition among three classes is not equivocal. Mostly, substitutions with positive effect on Fctriggered inhibition of mast cell degranulation also produce significant LTB 4 inhibition. This trend correlates in series 2 and 4, but regarding series 3, most of the substitutions at R 1 , R 2 and R 3 led to complete loss in LTB 4 inhibition. Exceptions are most lipophilic substituents like isopropyl at R 2 in 3o and at R 4 in 3p. Also combination of methyl at R 1 and chlorine at R 4 in series 3, led to very potent compound 3r. The most promising compounds were then selected for further evaluation in the in vivo antiinflammatory model of phorbol 12-myristate 13-acetate (PMA) induced ear oedema in CD1 mice (Table 5 ).
PMA induction of acute skin inflammation was conducted according to Napoletano et al. 49 with some modifications. PMA is tumor-promoting agent, and protein kinase C activator widely used to induce cutaneous inflammation in experimental animal models. Epicutaneous application of PMA results in vascular leakage, leukocyte infiltration, epidermal hyperplasia, activation of protein kinase C and increased release of arachidonic acid (AA) and its metabolites. 50 The initiation of inflammatory responses by metabolites of AA and suppression of acute inflammatory responses by inhibitors of cyclooxygenase (COX) and lypoxygenase (LOX) establish an important role for metabolites of AA in acute inflammation induced by AA and PMA. 51 Compounds 3r, 3p and 4p showed statistically significant suppression of ear eodema in comparison to positive control group, with comparable or even better activity to 5-LO and LTB 4 inhibitor zileuton.
These findings attracted us to extend our research to this class of compounds in the quest for antiinflammatory -antiallergic medication.
CONCLUSION
Several new series of coumarin compounds, hemiacetals 2, acetals 3, and rearranged compounds 4, have been synthesized and their inhibitory potential to prevent mast cell degranulation as well as LTB 4 production was evaluated. Significant inhibition of mast cell degranulation induced by the activation of Fcε receptor type I showed certain derivatives with alkyl and halogen substituents as well as combinations of those substituents, whereas unsubstituted compounds and those with hydroxy and methoxy substituents gave the poorest inhibitions.
Position R 1 is tolerated for Me substituent like in 2i and 3r. Majority of the active compounds are unsubstituted on position R 2 , however, some compounds with R 2 = iPr or Cl shown inhibition larger than 50 % (2d, 2o, 4o, 3l, 4l) . On the other hand, compounds with oxygen in R 2 (R 2 = OH and OMe) haven't shown any activity. Compounds 2e and 4e where R 3 = Cl shown inhibitor activity larger than 75 %. Position R 4 is tolerated for larger lipophilic substituents like Et (2n, 3n, 4n) and iPr (2p, 4p). Additionally, in combination with R 2 = Me, compounds where R 4 = Cl (3r) and Me (2i, 3i, 4i) shown the best activities in this set.
Significant inhibition of LTB 4 exhibited monoand bi-alkyl substituted compounds 2h-j, 2m-p, 3o-p, and 4o-p as well as 5-methyl-8-chloro substituted derivative 3r.
Selected compounds, 3p, 4p and 3r, exhibited significant anti-inflammatory activity in PMA induced ear edema in CD1 mice, with potency equal (compounds 3p and 4p) or better (compound 3r) in comparison with zileuton as the reference compound. This is very significant finding since it opens a new possibility of developing new class of non-steroidal compounds for the treatment of inflammatory diseases.
Further structural modifications are in progress with a view to shedding light on the better understanding of anti-inflammatory activity of 4-hydroxycoumarin compounds and critical structural parameters that affect biological activity.
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